← Back to all trials
Recruiting
NCT00923221
Collection of Blood From Patients With Prostate Cancer
Conditions: Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer, Prostate
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 1000
Sponsor: National Cancer Institute (NCI)
Location: National Institutes of Health Clinical Center Bethesda Maryland
Summary
Background:
* It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.
* Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.
* Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.
Eligibility:
-All participants participating in NCI prostate cancer protocols.
Design:
* Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
* Blood samples are collected at the initial visit or at follow-up visits.
* DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.
* Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Eligibility Criteria
* INCLUSION CRITERIA:
Individuals 18 years of age and older are eligible.
Individuals with a diagnosis of prostate cancer are eligible.
EXCLUSION CRITERIA:
Children are not eligible.
Source: ClinicalTrials.gov (NCT00923221). StuddyBuddy aggregates publicly available trial information.
